European Primary Care Cardiovascular Society
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A call to collect data on CV variables in patients with COVID-19

3' education - Apr. 14, 2020 - Prof. Folkert Asselbergs, MD, PhD

Rate of smoking cessation higher with e-cigarettes compared to counseling

3' education - Apr. 13, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Mechanistic evidence of CV benefit observed with icosapent ethyl

3' education - Apr. 12, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

A little closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 11, 2020 - Dirk Blom, PhD

sGC stimulator has added value in worsening HFrEF patients

3' education - Apr. 10, 2020 - Prof. Paul Armstrong, MD - ACC 2020

Reliable results with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Apr. 9, 2020 - Prof. Deepak Bhatt, MD

Significant reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 8, 2020 - Prof. Frederick Raal, PhD - ACC 2020

Better insight into current daily clinical practice and more collaboration is needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu

Why we need updated Diabetes Guidelines and new recommendations

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Policy recommendations to stimulate implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Cornelia Bala - European Diabetes Policy Summit

Implementation of guidelines: identifying barriers

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Old anti-inflammatory drug successfully repurposed for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, Boston - AHA 2019, Philadelphia

Anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Dec. 19, 2019 - Jean-Claude Tardif, Montreal - AHA 2019, Philadelphia

SGLT2i gives consistent CV benefit and tolerability in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, Glasgow - AHA 2019, Philadelphia

Fish oil may give favorable effects on plaque-parameters

3' education - Nov. 17, 2019 - Stephen Nicholls, Melbourne - AHA 2019, Philadelphia

A generation of teenagers is made addicted to nicotine: AHA stands up against 'big vape'

3' education - Nov. 17, 2019 - Mariell Jessup, Dallas - AHA 2019, Philadelphia

ARNI seems to give CV benefit up to EF of about 60%, not only in HFrEF

3' education - Nov. 16, 2019 - Scott Solomon, Boston - AHA 2019, Philadelphia

Management of diabetes during COVID-19 pandemic - practical recommendations

News - May 19, 2020

A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.

Hospitalized COVID-19 patients have a high risk of VTE

Literature - May 14, 2020 - Middeldorp S et al., - J Thromb Haemost 2020

Cumulative incidences of diagnosed and symptomatic VTE are increased in COVID-19 patients hospitalized in a Dutch hospital, with higher risk in those admitted to the ICU as compared to the general ward.

BMI standard deviation score reduced by GLP-1RA in obese adolescents

Literature - May 14, 2020 - Kelly AS et al., - N Engl J Med. 2020.

Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.

In ICU patients with COVID-19 pneumonia incidence of thrombotic complications is high

Literature - May 14, 2020 - Klok FA et al. - Thrombosis Research 2020
This observational study in 184 patients with COVID-19 pneumonia admitted to the ICU in the Netherlands showed a cumulative incidence of venous thromboembolism and arterial thrombotic complications of 31%.

This observational study in 184 patients with COVID-19 pneumonia admitted to the ICU in the Netherlands showed a cumulative incidence of venous thromboembolism and arterial thrombotic complications of 31%.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focuses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focuses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

Recommended use of RAS blockers during COVID-19

Literature - May 14, 2020 - Danser AHJ et al., - Hypertension 2020

This commentary article describes the function of ACE2, the receptor responsible for SARS-CoV-2 entry, and describes why continued use of RAS blockers during the COVID-19 pandemic is recommended.

FDA approves SGLT2i for treatment of HFrEF patients

News - May 12, 2020

The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.

Compared to 2019, increase in out-of-hospital cardiac arrests during the COVID-19 outbreak in Lombardia, Italy

Literature - May 11, 2020 - Baldi E, et al. - N Engl J Med 2020

In a letter to the editor, Baldi and colleagues describe a study on the incidence of out-of-hospital cardiac arrest in 4 provinces in Lombardy, Italy, during the initial outbreak of COVID-19.

Comparing P2Y12 inhibitors in NSTE-ACS patients aged 70 years or older

Literature - May 7, 2020 - Gimbel M, et al. - The Lancet 2020

In elderly patients, who have higher risk of bleeding and thrombotic events, treatment with clopidogrel reduced bleeding, while net clinical benefit was not increased compared to stronger P2Y12 inhibitors.

Total vascular events reduced by statin treatment after stroke or TIA

Literature - May 7, 2020 - Szarek M, et al. - J Am Coll Cardiol. 2020

Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.